Protocol No
ALEXION-ALXN1210-TMA-313
Principal Investigator
James Jerkins
Phase
III
Summary
This project is being done to see if a drug called ravulizumab will treat TMA after HSCT by
blocking complement activity.
Description
Ravulizumab in TMA after HSCT
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category
ClinicalTrials.gov